×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Antisense Oligonucleotide (ASO) Therapies for Neurodegenerat
therapeutic
938 words
KG: Antisense Oligonucleotide (ASO) Therapies for Neurodegenerative Diseases
2026-03-22
kind:therapeutic
section:therapeutics
state:published
Contents
Antisense Oligonucleotide (ASO) Therapies for Neurodegenerative Diseases
💊
Therapeutic Info
Name
Antisense Oligonucleotide (ASO) Therapies for Neurodegenerative Diseases
Summary
ASO therapies for AD, PD, ALS, HD - mechanism, clinical trials, and future directions
Knowledge Graph
Related Hypotheses (16)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Smartphone-Detected Motor Variability Correction
Score: 0.56
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44
Palmitoylation-Targeted BACE1 Trafficking Disruptors
Score: 0.41
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
APOE Isoform Conversion Therapy
Score: 0.44
R-Loop Resolution Enhancement Therapy
Score: 0.43
DNMT1-Targeting Antisense Oligonucleotide Reset
Score: 0.36
Show 11 more
Related Analyses (17)
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Show 12 more
Related Experiments (19)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Tau ASO Therapy
validation · proposed · Score: 0.40
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · proposed · Score: 0.40
Longitudinal TLR2 reporter gene study in α-synuclein mice
validation · proposed · Score: 0.90
Dexamethasone treatment study in α-synuclein mice
validation · proposed · Score: 0.85
TLR expression in α-synuclein overexpressing mice
validation · proposed · Score: 0.80
Show 14 more